Full Press Release Details
FOR MORE INFORMATION:
Senior Vice President, Finance and Strategy
954-384-0175, x 5692
Mednax Reports Second Quarter Results
FORT LAUDERDALE, Fla., August 6, 2021 - Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal, and
pediatric services, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing
operations of $0.41.
For the 2021 second quarter, Mednax reported the following results from continuing operations:
Strong patient volume trends across the spectrum of our service lines provided the foundation for strong second quarter results,
said Mark S. Ordan, Chief Executive Officer of Mednax. We believe these trends, combined with our focus on women s and children s care, operating efficiency and growth in many areas of pediatric subspecialty services,
together put us on a very positive forward path.
Operating Results from Continuing Operations Three Months Ended
Mednax s net revenue for the three months ended June 30, 2021 was $473.0 million, compared to
$415.4 million for the prior-year period. Mednax s overall same-unit revenue increased by 13.4 percent, slightly complemented by net acquisition activity.
Same-unit revenue attributable to patient volume increased by 9.5 percent for the 2021 second quarter as compared to the prior-year
period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three and six months ended June 30, 2021.
| Three Months Ended June 30, 2021 | Six Months Ended June 30, 2021 | |||
| Hospital-based patient services | 6.5% | 1.2% | ||
| Office-based patient services | 23.2% | 12.9% | ||
| Neonatology services (within hospital-based services): | ||||
| Total births | 2.9% | 1.2% | ||
| Neonatal intensive care unit (NICU) days | 4.4% | 1.1% |
Same-unit revenue from net reimbursement-related factors increased by 3.9 percent for the 2021 second
quarter as compared to the prior-year period. The net increase primarily reflects increases in contract administrative fees; modest improvements in managed care contracting; and an approximately 35 basis point increase in the percentage of services
reimbursed by commercial and other non-government payors. Partially offsetting these increases, during the 2021 second quarter, the Company did not record any funds under the Coronavirus Aid, Relief, and
Economic Security ( CARES ) Act, as compared to $5.8 million recorded during the 2020 second quarter. This decreased the Company s same-unit revenue from net reimbursement-related factors by 1.4 percent.
For the 2021 second quarter, practice salaries and benefits expense was $317.0 million, compared to $283.0 million for the
prior-year period. This increase reflects comparisons with the temporary reductions in salary expense related to COVID-19 cost mitigation initiatives during the 2020 second quarter, as well as current year
increases in variable incentive compensation, based on practice-level revenue and other financial results during the quarter.
2021 second quarter, general and administrative expenses were $71.0 million, as compared to $60.5 million for the prior-year period. This increase primarily reflects higher expenditures related to information-technology initiatives, as
well as comparisons with the temporary reductions in salary expense related to COVID-19 mitigation initiatives during the 2020 second quarter. During the second quarters of both 2021 and 2020, the Company
incurred approximately $3 million in expenses as part of the Company s transitional services being provided primarily to the buyer of the Company s former anesthesiology medical group. Mednax was reimbursed for these transition
services expenses and recorded such reimbursement within investment and other income, a component of net non-operating expenses.
During the second quarter of 2021, Mednax completed the sale of a secondary corporate office building, resulting in a gain on sale of
$7.3 million. This gain is being excluded from Adjusted EBITDA and Adjusted EPS.
For the second quarter of 2021, transformational
and restructuring related expenses totaled $9.9 million, compared to $10.5 million for the second quarter of 2020. Of the expense recorded during the second quarter of 2021, $6.2 million related to contract termination fees as part of
the Company s transition to a third-party revenue cycle management provider, while the remainder related primarily to third-party consulting fees.
Adjusted EBITDA from continuing operations, which is defined as earnings from continuing
operations before interest, taxes, depreciation and amortization, transformational and restructuring related expenses, and gain on sale of building was $65.5 million for the 2021 second quarter, compared to $55.7 million for the prior-year
period. Funds received from the provider relief fund established by the CARES Act impacted Adjusted EBITDA positively by approximately $3 million for the prior-year second quarter.
Depreciation and amortization expense was $8.1 million for the second quarter of 2021 compared to $6.8 million for the second
Investment and other income was $4.2 million for the second quarter of 2021 compared to $3.6 million for the
second quarter of 2020.
Interest expense was $16.9 million for the second quarter of 2021 compared to $28.3 million for the
second quarter of 2020. This decrease primarily reflects the Company s January 2021 redemption of its $750 million in outstanding principle amount of 5.25% senior notes due 2023 (the 2023 Notes ).
Mednax generated income from continuing operations of $30.5 million, or $0.36 per diluted share, for the 2021 second quarter, based on a
weighted average 85.9 million shares outstanding. This compares with income from continuing operations of $7.1 million, or $0.08 per diluted share, for the 2020 second quarter, based on a weighted average 83.7 million shares
For the second quarter of 2021, Mednax reported Adjusted EPS from continuing operations of $0.41, compared to $0.26 for the
second quarter of 2020. For these periods, Adjusted EPS from continuing operations is defined as diluted income from continuing operations per common and common equivalent share excluding non-cash amortization
expense, stock-based compensation expense, transformational and restructuring related expenses, gain on sale of building and discrete tax items as relevant to each period. For the six months ended June 30, 2021 Adjusted EPS also excludes the
loss on early extinghuisment of debt.
Operating Results from Continuing Operations Six Months Ended June 30, 2021
For the six months ended June 30, 2021, Mednax generated revenue from continuing operations of $919.7 million,
compared to $856.7 million in the prior-year period. Adjusted EBITDA from continuing operations for the six months ended June 30, 2021 was $111.0 million, compared to $88.8 million for the prior
year. Mednax generated income from continuing operations of $35.9 million, or $0.42 per share, for the six months ended June 30, 2021, based on a weighted average 85.7 million shares outstanding, which
compares to a loss from continuing operations of $11.4 million, or $0.14 per share, based on a weighted average 83.1 million shares outstanding for the first six months of 2020. For the six months ended June 30,
2021, Mednax reported Adjusted EPS from continuing operations of $0.65, compared to $0.32 in the same period of 2020.
Position and Cash Flow Continuing Operations
Mednax had cash and cash equivalents of $338.2 million at June 30, 2021,
compared to $1.12 billion on December 31, 2020, and net accounts receivable were $248.1 million. As previously disclosed, Mednax used $764 million in cash in January 2021 to redeem its $750 million 2023 Notes, including cash
premiums and accrued interest.
During the second quarter of 2021, Mednax generated cash from continuing
operations of $70.4 million, compared to $97.5 million during the second quarter of 2020. During the second quarter of 2021, the Company used $9.5 million to fund capital expenditures and $1.2 million to fund one
practice acquisition.
At June 30, 2021, Mednax had no outstanding borrowings under its $1.2 billion revolving credit facility
and had total debt outstanding of $1.0 billion, consisting solely of its senior notes due 2027, and net debt of $662 million.
Discontinued operations for the three and six months ended June 30, 2021 and 2020 includes the operating results of the
Company s former anesthesiology and radiology medical groups for relevant periods.
A reconciliation of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP
measures for the three and six months ended June 30, 2021 and 2020 is provided in the financial tables of this press release.
Mednax, Inc. will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast
may be accessed from the Company s Website, www.mednax.com. A telephone replay of the conference call will be available from 1:30 p.m. ET today through midnight ET August 20, 2021 by dialing 866.207.1041, access Code 6548348. The
replay will also be available at www.mednax.com.
Mednax, Inc. is a national medical group comprised of the nation s leading providers of physician services. Physicians and advanced
practitioners practicing as part of Mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient
outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico.
Additional information is available at www.mednax.com.
Certain statements and information in this press release may be deemed to contain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the Securities Act ), and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities,
events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as believe, hope, may,
anticipate, should, intend, plan, will, expect, estimate, project,
positioned, strategy and similar expressions, and are based on assumptions and assessments made by the Company s management in light of their experience and their
perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no
duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that
could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company s most recent Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q, including the sections entitled Risk Factors , as well the Company s current reports on Form 8-K, filed with the
Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the
Company s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with
managed care organizations and commercial health insurance payors; the Company s ability to comply with the terms of its debt financing arrangements; the Company s transition to a third-party revenue cycle management provider; the impact
of the divestiture of the Company s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company s
transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.
Consolidated Statements of Income
(in thousands, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net revenue | $ | 472,959 | $ | 415,441 | $ | 919,712 | $ | 856,686 | ||||||||
| Operating expenses: | ||||||||||||||||
| Practice salaries and benefits | 317,035 | 282,985 | 636,047 | 599,264 | ||||||||||||
| Practice supplies and other operating expenses | 24,182 | 20,173 | 46,394 | 44,015 | ||||||||||||
| General and administrative expenses | 70,968 | 60,488 | 137,484 | 127,930 | ||||||||||||
| Gain on sale of building | (7,280 | ) | (7,280 | ) | ||||||||||||
| Depreciation and amortization | 8,106 | 6,751 | 16,137 | 13,554 | ||||||||||||
| Transformational and restructuring related expenses | 9,932 | 10,479 | 14,810 | 26,555 | ||||||||||||
| Total operating expenses | 422,943 | 380,876 | 843,592 | 811,318 | ||||||||||||
| Income from operations | 50,016 | 34,565 | 76,120 | 45,368 | ||||||||||||
| Investment and other income | 4,176 | 3,576 | 10,143 | 2,530 | ||||||||||||
| Interest expense | (16,879 | ) | (28,265 | ) | (34,524 | ) | (55,930 | ) | ||||||||
| Loss on early extinguishment of debt | (14,532 | ) | ||||||||||||||
| Equity in earnings of unconsolidated affiliate | 577 | 305 | 1,072 | 799 | ||||||||||||
| Total non-operating expenses | (12,126 | ) | (24,384 | ) | (37,841 | ) | (52,601 | ) | ||||||||
| Income (loss) from continuing operations before income taxes | 37,890 | 10,181 | 38,279 | (7,233 | ) | |||||||||||
| Income tax provision | (7,363 | ) | (3,097 | ) | (2,408 | ) | (4,182 | ) | ||||||||
| Income (loss) from continuing operations | 30,527 | 7,084 | 35,871 | (11,415 | ) | |||||||||||
| Income (loss) from discontinued operations, net of tax | 4,478 | (679,520 | ) | 16,768 | (679,733 | ) | ||||||||||
| Net income (loss) | 35,005 | (672,436 | ) | 52,639 | (691,148 | ) | ||||||||||
| Net loss attributable to noncontrolling interest | 6 | 14 | ||||||||||||||
| Net income (loss) attributable to Mednax, Inc. | $ | 35,011 | $ | (672,436 | ) | $ | 52,653 | $ | (691,148 | ) | ||||||
| Per common and common equivalent share data (diluted): | ||||||||||||||||
| Income (loss) from continuing operations | $ | 0.36 | $ | 0.08 | $ | 0.42 | $ | (0.14 | ) | |||||||
| Income (loss) from discontinued operations | $ | 0.05 | $ | (8.11 | ) | $ | 0.19 | $ | (8.18 | ) | ||||||
| Net income (loss) attributable to Mednax, Inc. | $ | 0.41 | $ | (8.03 | ) | $ | 0.61 | $ | (8.32 | ) | ||||||
| Weighted average common shares | 85,933 | 83,744 | 85,653 | 83,061 |
Reconciliation of Income (Loss) from Continuing Operations
to Adjusted EBITDA from Continuing Operations Attributable to Mednax, Inc.
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Income (loss) from continuing operations attributable to Mednax, Inc. | $ | 30,533 | $ | 7,084 | $ | 35,885 | $ | (11,415 | ) | |||||||
| Interest expense | 16,879 | 28,265 | 34,524 | 55,930 | ||||||||||||
| Gain on sale of building | (7,280 | ) | (7,280 | ) | ||||||||||||
| Loss on early extinguishment of debt | 14,532 | |||||||||||||||
| Income tax provision | 7,363 | 3,097 | 2,408 | 4,182 | ||||||||||||
| Depreciation and amortization expense | 8,106 | 6,751 | 16,137 | 13,554 | ||||||||||||
| Transformational and restructuring related expenses | 9,932 | 10,479 | 14,810 | 26,555 | ||||||||||||
| Adjusted EBITDA from continuing operations attributable to Mednax, Inc. | $ | 65,533 | $ | 55,676 | $ | 111,016 | $ | 88,806 |
Reconciliation of Diluted Income (Loss) from Continuing Operations per Share
to Adjusted Income from Continuing Operations Attributable to Mednax, Inc. per Diluted Share ( Adjusted EPS )
(in thousands, except per share data)
| Three Months Ended June 30, | ||||||||||||||||
| 2021 | 2020 | |||||||||||||||
| Weighted average diluted shares outstanding | 85,933 | 83,744 | ||||||||||||||
| Income from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc. | $ | 30,533 | $ | 0.36 | $ | 7,084 | $ | 0.08 | ||||||||
| Adjustments (1) : | ||||||||||||||||
| Amortization (net of tax of $576 and $520) | 1,728 | 0.02 | 1,559 | 0.02 | ||||||||||||
| Stock-based compensation (net of tax of $1,434 and $1,605) | 4,301 | 0.04 | 4,812 | 0.07 | ||||||||||||
| Transformational and restructuring expenses (net of tax of $2,483 and $2,620) | 7,449 | 0.09 | 7,859 | 0.09 | ||||||||||||
| Gain on sale of building (net of tax of $1,820) | (5,460 | ) | (0.06 | ) | ||||||||||||
| Net impact from discrete tax events | (3,516 | ) | (0.04 | ) | 110 | |||||||||||
| Adjusted income and diluted EPS from continuing operations attributable to Mednax, Inc. | $ | 35,035 | $ | 0.41 | $ | 21,424 | $ | 0.26 |
| Six Months Ended June 30, | ||||||||||||||||
| 2021 | 2020 | |||||||||||||||
| Weighted average diluted shares outstanding | 85,653 | 83,061 | ||||||||||||||
| Income (loss) from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc. | $ | 35,885 | $ | 0.42 | $ | (11,415 | ) | $ | (0.14 | ) | ||||||
| Adjustments (1) : | ||||||||||||||||
| Amortization (net of tax of $1,466 and $1,032) | 4,400 | 0.05 | 3,094 | 0.04 | ||||||||||||
| Stock-based compensation (net of tax of $2,363 and $3,418) | 7,089 | 0.08 | 10,254 | 0.12 | ||||||||||||
| Transformational and restructuring expenses (net of tax of $3,702 and $6,639) | 11,108 | 0.13 | 19,916 | 0.24 | ||||||||||||
| Gain on sale of building (net of tax of $1,820) | (5,460 | ) | (0.06 | ) | ||||||||||||
| Loss on early extinguishment of debt (net of tax of $3,633) | 10,899 | 0.13 | ||||||||||||||
| Net impact from discrete tax events | (8,583 | ) | (0.10 | ) | 4,944 | 0.06 | ||||||||||
| Adjusted income and diluted EPS from continuing operations attributable to Mednax, Inc. | $ | 55,338 | $ | 0.65 | $ | 26,793 | $ | 0.32 |